Scoploamine in the treatment of major depression

Scopolamine as adjuvant therapy in the treatment of major depression: a randomised and double blind study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201201181556N31

Enrollment

Registered

2012-01-19

Start date

2011-11-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive episode. Major Depressive episode

Interventions

Intervention 1: Tablet Citalopram 40 mg/day plusTablet Scoplolamine 10 mg/day as intervention group for 6 weeks. Intervention 2: Tablet Citalopram 40 mg/day plus Tablet placebo as control group for 6

Treatment - Drugs

Placebo

Tablet Citalopram 40 mg/day plusTablet Scoplolamine 10 mg/day as intervention group for 6 weeks

Tablet Citalopram 40 mg/day plus Tablet placebo as control group for 6 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Presence of Major Depressive Disorder based on DSM-IV criteria; Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 22. Exclusion criteria: Presence of Psychosis, any other diagnosis in Axis I and II; Receiving psychotropic medications; receiving any antidepressants during past one month or ECT during past two months; Presence of hypothyroidism or cardiovascular problems and pregnancy or nursing women

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: Baseline and day 4, 7 , 14, 28, and 42. Method of measurement: Hamiltion Depression Rating Scale 17-Item.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 25, 2026